ENGERIX-B (ADULT)

Valsts: Indonēzija

Valoda: indonēziešu

Klimata pārmaiņas: Badan Pengawas Obat dan Makanan RI - Indonesian Food and Drug Supervisory Agency

Aktīvā sastāvdaļa:

HEPATITIS B SURFACE ANTIGEN

Pieejams no:

GLAXO WELLCOME INDONESIA - Indonesia

SNN (starptautisko nepatentēto nosaukumu):

HEPATITIS B SURFACE ANTIGEN

Deva:

20 MCG

Zāļu forma:

SUSPENSI INJEKSI

Vienības iepakojumā:

DUS, 1 PREFILLED SYRINGE @ 1 ML (1 DOSISI)

Ražojis:

GlaxoSmithKline Biologicals SA - Belgium

Autorizācija datums:

2021-12-31

Produkta apraksts

_ENGERIX-B _
HEPATITIS B (RDNA) VACCINE (ADSORBED)
SUSPENSION FOR INJECTION
QUALITATIVE AND QUANTITATIVE COMPOSITION
10 ΜG DOSE VACCINE
1 dose (0.5 mL) contains:
Hepatitis B surface antigen
1, 2
10 micrograms
1
Adsorbed on aluminium hydroxide, hydrated
Total: 0.25 milligrams Al
3+
2
Produced in yeast cells (_Saccharomyces cerevisiae_) by recombinant
DNA technology
20 ΜG DOSE VACCINE
1 dose (1 mL) contains:
Hepatitis B surface antigen
1, 2
20 micrograms
1
Adsorbed on aluminium hydroxide, hydrated
Total: 0.50 milligrams Al
3+
2
Produced in yeast cells (_Saccharomyces cerevisiae_) by recombinant
DNA technology
The vaccine is highly purified, and exceeds the WHO requirements for
recombinant hepatitis B vaccines.
No substances of human origin are used in its manufacture.
Turbid white suspension.
Upon storage, a fine white deposit with a clear colourless supernatant
may be observed.
CLINICAL INFORMATION
INDICATIONS
_ENGERIX-B_ is indicated for active immunization against hepatitis B
virus (HBV) infection caused by all
known subtypes in subjects of all ages considered at risk of exposure
to HBV. It can be expected that
hepatitis D will also be prevented by immunization with _ENGERIX-B _as
hepatitis D (caused by the delta
agent) does not occur in the absence of hepatitis B infection.
Immunization against hepatitis B is expected in the long term to
reduce not only the incidence of this
disease, but also its chronic complications such as chronic active
hepatitis B and hepatitis B associated
cirrhosis.
In areas of LOW PREVALENCE of hepatitis B, immunization is
particularly recommended for those belonging
to groups identified at increased risk of infection (see below),
however, universal immunization of all
infants and adolescents will contribute to the control of hepatitis B
on a population basis.
In areas of INTERMEDIATE AND HIGH PREVALENCE of hepatitis B, with most
of the population at risk of
acquiring the HBV, the best strategy is to provide universal
immunization of neonates, infants, children
and adolescents, as wel